{"Symbol": "ABVX", "AssetType": "Common Stock", "Name": "Abivax SA American Depositary Shares", "Description": "Abivax SA is a clinical-stage biotechnology company dedicated to advancing innovative immunotherapies for chronic inflammatory diseases and viral infections. Its lead product candidate, ABX464, is undergoing clinical trials for ulcerative colitis and potentially other therapeutic indications, indicating a strong focus on addressing major unmet medical needs. By leveraging a unique approach that combines antibody-mediated treatments with proprietary compounds, Abivax aims to significantly improve patient outcomes. With a robust development pipeline and a committed scientific team, Abivax presents compelling investment opportunities for institutional investors looking to capitalize on the expanding immunotherapy landscape.", "CIK": "1956827", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "7-11 BOULEVARD HAUSSMANN, PARIS, FRANCE, 75009", "OfficialSite": "https://www.abivax.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-06-30", "MarketCapitalization": "8187962000", "EBITDA": "-185652000", "PERatio": "None", "PEGRatio": "None", "BookValue": "-0.761", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-3.58", "RevenuePerShareTTM": "0.095", "ProfitMargin": "0", "OperatingMarginTTM": "-44.41", "ReturnOnAssetsTTM": "-0.577", "ReturnOnEquityTTM": "-4.998", "RevenueTTM": "6023000", "GrossProfitTTM": "6023000", "DilutedEPSTTM": "-3.58", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.813", "AnalystTargetPrice": "123.78", "AnalystRatingStrongBuy": "4", "AnalystRatingBuy": "6", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "1860.91", "PriceToBookRatio": "16.28", "EVToRevenue": "157.63", "EVToEBITDA": "-12.66", "Beta": "-0.111", "52WeekHigh": "148.83", "52WeekLow": "4.77", "50DayMovingAverage": "90.96", "200DayMovingAverage": "37.83", "SharesOutstanding": "77829000", "SharesFloat": "35270700", "PercentInsiders": "0.000", "PercentInstitutions": "49.008", "DividendDate": "None", "ExDividendDate": "None"}